Clinical Trial Update: Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating camrelizumab for high-risk non-muscle-invasive bladder cancer that failed BCG treatment, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Fudan University | Conditions: Urinary Bladder Neoplasms, Immunotherapy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING